IMVT

Immunovant Inc. Healthcare - Biotechnology Investor Relations →

NO
27.3% ABOVE
↑ Moving away Was 23.0% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $21.25
14-Week RSI 60

Immunovant Inc. (IMVT) closed at $27.05 as of 2026-02-02, trading 27.3% above its 200-week moving average of $21.25. The stock moved further from the line this week, up from 23.0% last week. The 14-week RSI sits at 60, indicating neutral momentum.

Over the past 298 weeks of data, IMVT has crossed below its 200-week moving average 3 times. On average, these episodes lasted 45 weeks. Historically, investors who bought IMVT at the start of these episodes saw an average one-year return of +14.2%.

With a market cap of $5.5 billion, IMVT is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -69.3%. The stock trades at 5.6x book value.

Share count has increased 46.0% over three years, indicating dilution.

Over the past 5.8 years, a hypothetical investment of $100 in IMVT would have grown to $105, compared to $246 for the S&P 500. IMVT has returned 0.9% annualized vs 16.7% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 1 open-market purchase totaling $440,333,316.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: IMVT vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After IMVT Crosses Below the Line?

Across 3 historical episodes, buying IMVT when it crossed below its 200-week moving average produced an average return of +21.5% after 12 months (median +108.0%), compared to +23.0% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was +1.0% vs +23.5% for the index.

Each line shows $100 invested at the moment IMVT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

1 conviction buy in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2025-12-12ROIVANT SCIENCES LTD.Director and Beneficial Owner of more than 10% of a Class of Security$440,333,31616,666,666+17.2%

Historical Touches

IMVT has crossed below its 200-week MA 3 times with an average 1-year return of +14.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Feb 2021Dec 20229680.1%-75.4%+21.8%
Mar 2023Apr 202379.8%+103.8%+74.0%
Mar 2025Oct 20253125.8%N/A+47.3%
Average45+14.2%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02